Dataset from A Phase 2b/3, Randomized, Double-Blind Study Comparing Upadacitinib (ABT-494) to Placebo in Japanese Subjects With Moderately to Severely Active Rheumatoid Arthritis Who Are on a Stable Dose of Conventional Synthetic Disease-Modifying Anti-Rheumatic Drugs (csDMARDs) and Have an Inadequate Response to csDMARDs
收藏NIAID Data Ecosystem2026-05-02 收录
下载链接：
https://doi.org/10.25934/PR00009775
下载链接
链接失效反馈官方服务：
资源简介：
This is a randomized, double-blind study comparing ABT-494 to placebo in Japanese
participants with moderately to severely active rheumatoid arthritis who are on a stable dose
of conventional synthetic disease-modifying anti-rheumatic drugs (csDMARDs) and have an
inadequate response.
Following marketing approval of upadacitinib for rheumatoid arthritis in Japan, this study
will become a post-marketing clinical study and include a long-term extension period.
创建时间：
2024-11-26
